. Release of As schematically shown in Fig. 1 [1] [2] [3] [4] [5] [6] [7] [8] [9] ; simultaneously, albumin and transferrin concentrations decrease. These changes in plasma levels of acute phase proteins are preceded by corresponding alterations in mRNA concentrations. In addition, increases in the rates of secretion of some acute phase proteins have been observed.
The earliest description of the acute phase response came from the ancient Greeks [10] . They already observed an increased sedimentation rate of erythrocytes in blood of severely ill patients. As we know today, this increase is due to elevated plasma concentrations of fibrinogen and other acute phase proteins [11] . The term 'acute- [12] , who described the properties of sera from patients with febrile infectious diseases. These sera contained an acute phase protein (C-reactive protein), which was induced during febrile infections. Search for hepatocyte-stimulating factors In 1951 it was shown by Miller et al. [13] that liver is the major organ for the synthesis of acute phase proteins. Since the acute phase proteins are synthesized in the liver and injury to another part of the body results in increased synthesis of acute phase proteins, the existence of hormone-like mediators was proposed. For many years investigators have been searching for such mediators. Since leukocytes are the cells first attracted at the sites of injury, they were examined as candidates for the synthesis and release of such mediators. Indeed, leukocyte super-
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Abbreviations used: IL, interleukin; TNF, tumour necrosis factor; CSF, colony stimulating factor. § To whom correspondence should be addressed. [18] . In the following years several laboratories attempted to purify and characterize the hepatocyte-stimulating factor produced by monocytes [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] , rat Kupffer cells [30] [31] [32] , human keratinocytes [19] and leukaemia cell lines [21, 27] . The molecular mass of the hepatocyte-stimulating factor from human monocytes was estimated by gel chromatography to be 23-30 kDa [19] [20] [21] [25] [26] [27] [28] [29] . An isoelectric point of approx. 5.4 has been determined [27] . The production of hepatocyte-stimulating factor by human monocytes was found to be regulated by lipopolysaccharide in a dosedependent manner [26] . Discrimination of hepatocyte-stimulating factor from interleukin-1 and tumour necrosis factor a Since human monocytes also release IL-I and TNFa after stimulation with lipopolysaccharide, it was investigated whether these two monokines could act as hepatocyte-stimulating factors. The availability of recombinant human IL-I and TNFa allowed such studies.
Whereas the synthesis of rat haemopexin, complement C3, haptoglobin, a,-acid glycoprotein, albumin, murine serum amyloid A, and P, and human metallothionein was regulated by IL-1 [33] [34] [35] [36] [37] [38] 39] , the synthesis of the majority of acute phase proteins could not be stimulated by IL-1 [20] [21] [22] 26, 28, 29, 34, 36, 38] . Recombinant human TNFa showed a very limited effect on a subset of acute phase proteins [28, 29, [34] [35] [36] .
Identification of interleukin-6/B-cell stimulatory factor-2 as hepatocyte-stimulating factor After the discrimination of IL-1 and TNFoc from hepatocyte-stimulating factor, interferons were examined as potential hepatocyte-stimulating factors. Highly purified interferon-fl contained hepatocyte-stimulating activity, absent from recombinant human interferon-fl, interferon-a, and recombinant human interferon-y, indicating that hepatocyte-stimulating factor copurified, but was distinct from, interferon-fl1 [40] . Gauldie et al. [41] reported that antibodies raised against interferon-f (1I + f2) from fibroblasts inhibited hepatocyte-stimulating activity derived from human monocytes.
In 1986/87 interferon-fl2 was shown to be identical with B-cell stimulatory factor-2, hybridoma plasmacytoma growth factor, 26 kDa protein [42] [43] [44] and the name interleukin-6 was proposed for this molecule [45] ( Table 2) . Using recombinant B cell stimulatory factor-2, Gauldie et al. [41] presented the first evidence that hepatocyte-stimulating factor is identical with IL-6. BSF-2/IL-6 induced the synthesis of 8-fibrinogen, aL-antichymotrypsin, a1-acid glycoprotein and haptoglobin in HepG2 cells, and a2-macroglobulin and cysteine protease inhibitor in rat hepatocytes. Furthermore, in rat hepatocyte primary cultures [38] , or in the rat hepatoma cell lines Fao and H-35 [40, [46] [47] [48] , IL-6 led to a dose-and time-dependent regulation of ac2-macroglobulin, 8-fibrinogen, cysteine protease inhibitor, a1-acid glycoprotein, angiotensinogen and albumin. A concentration of 30 pM of recombinant human IL-6 resulted in a half-maximal acute phase response in hepatocyte primary cultures. A maximal response was achieved at a concentration of 1 nm recombinant human IL-6 [38] . IL-6 also had a stimulatory effect on the secretion of acute phase proteins [38] .
Since in vivo stimulated monocytes synthesize and secrete IL-6, IL-I and TNFa, the possible interaction of these cytokines was studied. IL-I was able to inhibit the stimulatory effect of IL-6 on the synthesis of a2-macroglobulin, cysteine protease inhibitor and fibrinogen in rat hepatocyte primary cultures, while TNFa did not affect the action of IL-6 [36, 38, 41] . This finding suggests a complex regulation of acute phase protein synthesis. Induction of rat acute phase proteins by interleukin-6 in vivo After the demonstration that IL-6 is a potent inducer of acute phase protein synthesis in rat hepatoma cells and in adult rat hepatocytes, the validity of these observations remained to be demonstrated under in vivo conditions. The administration of recombinant human IL-6 to rats led to increases in the hepatic mRNA levels of a2-macroglobulin, f,-fibrinogen, cysteine protease inhibitor and al-acid glycoprotein and to a simultaneous decrease in albumin mRNA concentrations [49] . When the time course of acute phase protein mRNA induction after the administration of recombinant human IL-6 was 1990 compared with that after intramuscular injection of turpentine (commonly used for the induction of the acute phase response) a more rapid induction of the ,3-fibrinogen and a2-macroglobulin mRNA levels was observed in the case of recombinant human IL-6 [49] . This delay in acute phase response could be due to an indirect action of turpentine, where a cascade of reactions including activation of inflammatory cells and the formation, secretion and transport of acute phase mediators from the local abscess to the liver had to proceed, whereas recombinant human IL-6 acted directly on the hepatocytes. These results were recently confirmed [50] . Also in mice, induction of serum amyloid A, complement factor B and fibrinogen was activated after the injection of recombinant human [51, 52] .
ACTIONS OF INTERLEUKIN-6
Interleukin-6 is the major regulator of the acute phase response in human hepatocytes First evidence for IL-6 as an inducer of the acute phase response in the human system came from work with human cell lines [41, [53] [54] [55] [56] [57] [58] . As shown in Table 3 , upper part, increases in protein synthesis of 8-fibrinogen, acxantichymotrypsin, caeruloplasmin, haptoglobin, ai-acid glycoprotein, ax-antitrypsin, and complement factor B are observed upon stimulation of HepG2 cells with recombinant human IL-6. However, no induction of the major human acute phase proteins, C-reactive protein and serum amyloid A, could be observed in IL-6-stimulated HepG2 or Hep3B cells. The combination of IL-6 and IL-1 was required to stimulate C-reactive protein and serum amyloid A synthesis in Hep3B cells [54] . Only in NPLC/PRF/5 cells could an IL-6-dependent stimulation of C-reactive protein and serum amyloid A synthesis be detected [54] . First evidence for IL-6 as the major inducer of acute phase proteins in humans came from studies with human hepatocytes in primary culture. In this system IL-6 was capable of inducing C-reactive protein and serum amyloid A synthesis in a dose-and time-dependent manner (Figs. 2a and 2b) [59] (Table 3 , lower part). Since several investigators have found that IL-1 [5, [33] [34] [35] [36] [37] 46, 60] and TNFa [34, 35] were inducers of acute phase protein synthesis, comparative studies on the induction of various acute phase proteins by the three monokines have been carried out in human hepatocyte primary cultures [61, 62] . While IL-6 stimulated the full spectrum of acute phase proteins seen in inflammatory states in man, IL-I as well as TNFa had only a moderate effect on the positive acute phase proteins [62] . Both inhibited the synthesis of f,-fibrinogen, albumin and transferrin and failed to induce serum amyloid A and C-reactive protein [62] . These data strongly suggest that IL-6 plays a key role in human acute phase protein synthesis.
Recently IL-6 has been found to stimulate synthesis of the acute phase proteins complement factor B and C3 in human skin fibroblasts [63] . Pleiotropic action of interleukin-6
Besides its effect on hepatocytes, IL-6 acts on several other target cells (Fig. 3 , and briefly reviewed in [73, 74] ). The biological functions of IL-6 under different names have been studied in various laboratories with a variety of cell systems (Table 2 ). When sequence data and specific antibodies became available after the purification and cDNA cloning of these 'different factors', they turned out to be identical. To unify the nomenclature, Poupart et al. [45] and Yasukawa et al. [75] proposed the name interleukin-6 for this molecule. Although this name is somewhat misleading, because interleukin-6 is synthesized by and acts on leukocytic and non-leukocytic cells, it was accepted at a conference of the New York Academy of Sciences and the National Foundation for Cancer Research in New York in December 1988 by the majority of the investigators in the field [76] .
Action of interleukin-6 on B-and T-lymphocytes, plasmacytoma and B cell hybridomas. IL-6 acts directly on B cells activated by and IL-5 and induces immunoglobulin M, G, and A production, i.e. IL-6 plays an essential role in the terminal differentiation of B cells into immunoglobulin-secreting cells (Fig. 3) [64, 65, [77] [78] [79] . IL-6 does not act on normal resting B cells, because these cells do not express IL-6 receptors [80] . Although activated B cells express IL-6 receptors, and respond to IL-6 by antibody production and secretion, IL-6 does not exert any growth-promoting activity on these cells.
Also in vivo, IL-6 has been shown to augment primary and secondary antibody responses in mice [81] . The strongest effect of IL-6 was observed in the secondary response [81] . After transfection with Epstein-Barr virus, B cells have been described to respond to IL-6 with proliferation in a paracrine manner [82] . IL-6 functions as a potent growth factor in plasmacytoma cells [70, 71, [83] [84] [85] [86] . IL-6 and IL-3 synergistically promote the proliferation and differentiation of malignant plasma cell precursors in multiple myeloma [87] . Myeloma cells from patients produce and express its receptors. Antibodies against IL-6 inhibited the growth of these cells, suggesting an autocrine loop involved in oncogenesis of human myelomas [85] . Autocrine loops have also been proposed for the astroglyoma cell line U 337 and the myeloid cell line HL 60 [77] , since both express IL-6 and IL-6 receptor [77] . Human [93] established a stable cell line (B9), which can be used in a highly sensitive IL-6 assay detecting pg amounts of IL-6. This bioassay is highly specific for IL-6. The only known weak cross-reacting cytokine is murine interleukin-4 [93] . A similar B cell hybridoma clone (MH60. BSF2) suitable for the detection of IL-6 has been obtained by Kishimoto's group [94] .
IL-6 is an important helper factor in primary antigenreceptor-dependent T cell activation and subsequent proliferation of the activated T cells [95] [96] [97] [98] [99] [100] [101] . This IL-6 action is synergized by IL-1 [99, 100] and has been found to be IL-2-dependent [95, 96, 97] [93, 102, 103] and stimulates proliferation of the thymocytes via an IL-2-dependent and -independent pathway [104, 105] . Also in the late phase of cytotoxic Tcell generation IL-6 seems to enhance the action of IL-2 [106, 107] .
From the papers referred to in this section it becomes clear that IL-6 is involved in the function of the immune system by stimulating humoral as well as cellular defence mechanisms. Furthermore, IL-6 primes the human neutrophil and monocyte oxidative burst response [108] .
Interleukin-6 is involved in haematopoiesis. IL-6 enhances the proliferation of multipotential haematopoietic progenitors in the human [109-1 1 1] , murine [1 12-118] and rat [119] systems. A synergistic action of IL-6 with IL-3 [109, [112] [113] [114] [115] [116] , [117] , GM-CSF [111] and M-CSF [110] has been described. It has been suggested that IL-6 shortens the Go period of haematopoietic stem cells by stimulating the proliferation of these cells [109, 112, 116] .
Action of interleukin-6 on the growth and differentiation of various cell types. In addition to the function of IL-6 as a growth and differentiation factor in the haematopoietic and immune system, IL-6 has been described to stimulate proliferation of human [120, 121] and murine [72, 122, 123] leukaemia and human lymphoma cells [124] . Interestingly, IL-6 also exerts a strong inhibition on the growth of human fibroblasts [125] , of leukaemia [126, 127] , lymphoma [126] and breast carcinoma cells [126] , and of human endothelial cells in culture [128] . Since fibroblasts and endothelial cells synthesize IL-6, the growth of these cells may be controlled via a negative autocrine feedback loop. As described above, a positive autocrine feedback loop was observed in plasmacytoma cells [85] . Further investigations of these two differently regulated systems might lead to a better understanding of growth control and oncogenesis. Furthermore, IL-6 plays a role in the expression of class I histocompatibility antigens in human fibroblasts [129] .
In murine myeloleukaemic M1 cells and in human histiocytic U 937 cells, IL-6 induces morphological and functional differentiation into macrophages [130] . promotes maturation of murine megakaryocytes [131] .
Recently IL-6 has also been found to be involved in neuronal differentiation. Pheochromocytoma PC 12 cells change morphologically to neurite-extending cells [132] . In pituitary cells [133] and in the rat in vivo [134] IL-6 triggers the release of ACTH. Since ACTH stimulates glucocorticoid synthesis and glucocorticoids suppress IL-6 synthesis in monocytes, a bidirectional communication system regulating IL-6 levels exists between the neuroendocrine and the immune system.
Besides IL-1 and TNFa, has been found to be an endogeneous pyrogen [93] . Intravenous injection of human recombinant IL-6 into rabbits led to a rapid onset of fever reaching a peak at 60 min after injection [93] . Although IL-6 initially was described as an interferon, its antiviral activity is weak [66, 125, [135] [136] [137] and several groups of investigators could not detect any antiviral activity at all [44, 69, [138] [139] [140] .
STRUCTURE OF THE IL-6 GENE The human IL-6 gene is located on the short arm of chromosome 7 p15-p21 [141] [142] [143] , and the murine IL-6 gene maps to the proximal region of chromosome 5 [144] . Chromosomal abnormalities of human chromosomes 7 and 5 have been found to be associated with a variety of haematopoietic disorders, among them multiple myeloma. Both human and mouse IL-6 genes consist of five exons and four introns [145, 146] . This gene organization is highly homologous to that of the G-CSF gene, an indication for the possible evolution from a common ancester gene. Three initiation sites for transcription differently used in different cell types have been found [145] . At the 5' boundary of the IL-6 gene between -225 and -113, motifs similar to the regulatory elements in the human c-fos gene exist and may contain the major cis-acting elements responsible for the activation of the IL-6 promoter [146, 147] . Furthermore, several putative enhancer and mediator responsive elements for cyclic AMP, glucocorticoid receptor, and activator binding protein-1 (AP-1) are present in the highly conserved 5' flanking region of the IL-6 gene of man and mouse [146] .
STRUCTURE OF IL-6 PROTEIN
The nucleotide sequences and the corresponding amino acid sequences obtained by cDNA cloning of the IL-6 mRNA from human fibroblasts [69, 135] , from transformed human T cells [65] and from human monocytes [148, 149] [68] . After removal of a 28-amino-acid signal peptide, the resulting 184-amino-acid protein, containing two possible Nglycosylation sites, is N-and O-glycosylated and subsequently secreted [150] [151] [152] [153] [154] . The IL-6 secreted by monocytes shows a similar glycosylation pattern as that from fibroblasts, consisting of five or six different forms, which are the result of different N-and O-glycosylation [150] [151] [152] [153] [154] . Furthermore, the fibroblast and monocyte IL-6 is phosphorylated at several serine residues [155] . No sulphation was observed [155] . Although the unglycosylated IL-6 is biologically active, these post-translational modifications may play a role in tissue-specific functions and/or in plasma half-life.
Murine IL-6 contains 211 amino acids, including a signal peptide of 24 residues. No N-glycosylation, but several O-glycosylation, sites were identified in this sequence. The sequence similarity to human IL-6 is 650 at the cDNA level [156] and 420 at the protein level [92] . In spite of the low similarity it is remarkable that both IL-6 species are biologically active in heterologous systems.
Human granulocyte colony stimulating factor (G-CSF) is the only presently known protein with some sequence similarity to human IL-6 [65] . Moreover, the cysteine locations in human and murine IL-6 match very well with those in G-CSF [65, 157] .
REGULATION OF INTERLEUKIN-6 BIOSYNTHESIS
The multifunctional cytokine IL-6 is synthesized by many different cells after appropriate stimulation (Table  4) . Also, several tumour cell lines produce IL-6 spontaneously (Table 5 ). However, endothelial cells, fibroblasts and monocytes/macrophages are probably the major sources of IL-6 during systemic inflammation. Evidence for this assumption is based on the following facts: (a) these cells are highly abundant and widely distributed in the organism, (b) they have a high capacity to synthesize and secrete IL-6, and (c) IL-6 production can be triggered by several stimulators (Table 4) . From the data summarized in Table 4 , it can be seen that monocytes/macrophages are preferentially stimulated by bacterial lipopolysaccharide, whereas fibroblasts and endothelial cells respond better to the endogenous cytokines IL-1 and TNFac otherwise abundantly synthesized by monocytes/macrophages, suggesting that they play a key role in the production of IL-6.
In agreement with the results obtained from the experiments in vitro summarized in Tables 4 and 5 are the observations of elevated IL-6 serum levels after intravenous-injection oflipopolysaccharide [185, 186] or TNFa [187, 188] into human volunteers and during bacterial infection [189] .
The cytokines IL-1 and TNFa, which stimulate the synthesis of IL-6 in human fibroblasts, act via two second messenger systems: protein kinase C [190] and cyclic AMP [163, 164] . Furthermore, synthesis is controlled by steroid hormones. Dexamethasone has been described to inhibit IL-6 production in human monocytes [23] and in the astrocytoma cell line U373 MG [181] . Oestradiol-17,6 impaired IL-6 formation in -human endometrial stromal cells [178] .
Using Finally, it has been observed in several laboratories that the incubation of fibroblasts with cycloheximide leads to an accumulation of IL-6 mRNA [68, 69, 160] . This finding may be explained by the presence of two blocks of AU-rich sequences in the 3' untranslated region of IL-6 mRNA containing the AUUUA motif thought to be involved in the degradation of mRNA [162, 191] . The AUUUA motif has been found in the 3' flanking region of many short-lived cytokine mRNAs [192] .
Since IL-6 is found in cerebrospinal fluid [193] [194] [195] and in synovial fluid [196] [197] [198] during bacterial and viral infection of the central nervous system and during inflammatory arthritis, other cells, such as astroglia, microglia and synoviocytes, may be important sources of IL-6 during local inflammation.
HEPATOCYTES AS TARGET CELLS FOR INTERLEUKIN-6
As described above, IL-6 acts on many different target cells in vitro. In vivo, the liver seems to be the major target organ for IL-6. Both biological activity and radioactivity of 125-I-labelled recombinant human IL-6 injected intravenously into rats disappeared very rapidly from the circulation. The kinetics of clearance is biphasic and consists of a rapid initial elimination corresponding to a half-life of about 3 min and of a second slower decrease corresponding to a half-life of about 55 min [199] . Recombinant human IL-6 associates with a plasma protein resulting in a complex with f-y mobility upon cellulose acetate electrophoresis [199] . In Kishimoto's laboratory a2-macroglobulin has been identified as a carrier for IL-6 [200] . IL-6 bound to z2-macroglobulin retained its biological activity and became resistant to proteases [200] . However, in our laboratory (J. V. Castell & P. C. Heinrich, unpublished results) a2-macroglobulin could not be identified as a binding protein for IL-6.
An analysis of the organs involved in the clearance of recombinant human IL-6 showed that the liver is the major target organ for IL-6. At 20 min after injection about 800 of the 1251I-labelled recombinant human IL-6 had disappeared from the circulation and was found in liver [199] . Within the liver, 1251-labelled recombinant human IL-6 was exclusively localized on the surface of parenchymal cells, suggesting the existence of an IL-6 receptor on the plasma membrane of hepatocytes [199] . As expected from the pleiotropic action of IL-6, IL-6 receptors have been found on the surface of various cell lines [201, 202] . IL-6-receptor cDNA has recently been cloned [203] .
INTERACTION OF INTERLEUKIN-6 WITH ITS HEPATIC RECEPTOR AND SIGNAL TRANSDUCTION Interleukin-6 receptor
The IL-6-receptor cDNA was obtained from a cDNA library constructed from poly(A) RNA of the human natural killer cell line YT [203] . The IL-6-receptor cDNA encoded a protein consisting of 468 amino acids including Vol. 265 [18, 26, 150, 152] ttt [158] [ 150, 152] t [153] t [153] 0/T and 1011 M for '25I-labelled recombinant human IL-6 were determined in several T-and B-cell, myeloid and astrocytoma cell lines [201, 202] . Except for the plasma cell line U266 (11 000 sites/cell) the number of IL-6 receptors per cell in these cell lines is low (1000) or very low ( < 200) [201] .
Little is known about the hepatic IL-6 receptor. In the 1990 human hepatoma cell line HepG2 450 + 00 high-affinity (Ka 6.7 x 1010 M)and 5000low-affinity (Ka 2 x l09 M)binding sites were determined [204] . A high-affinity association constant Ka of 77 x 1010 M and about 1500 IL-6 receptors were determined when the binding of 1251-labelled recombinant human IL-6 to sinusoidal membranes from rat liver was studied (E. Hipp, unpublished work). No evidence for an internalization of '25I-labelled recombinant human IL-6 by HepG2 cells and by rat hepatocytes in vivo was obtained [205] . A similar observation has been described by Aarden et al. [206] , who found that IL-6 was neither taken up nor consumed by B-cell hybridomas. In contrast, 1251I-labelled recombinant human IL-6 was found to be internalized by CESS cells [202] . Affinity cross-linking using 1251I-labelled recom- binant human IL-6 and sinusoidal membranes from rat, pig or human liver resulted in the detection of a complex between IL-6 and its receptor with an apparent molecular mass of 100 kDa (arrow, Fig. 4 ). Therefore, a molecular mass of 80 kDa for the hepatic IL-6 receptor protein is suggested (D. Lenz, unpublished work). In the human lymphoplastoid cell line CESS, Coulie et al. [202] found three IL-6-binding proteins of about 170, 140 and 90 kDa. Content et al. [207] observed in HepG2 cells an increased binding of IL-6 after incubation with dexamethasone. This effect was due to an increase in the number of IL-6 binding sites and not to an increased affinity of IL-6 for its receptor. This is in accordance with data of H. Schooltink (unpublished results), who found increased IL-6-receptor mRNA levels after treatment of HepG2 cells with dexamethasone (Fig. 5) . In fetal human hepatocytes in primary culture IL-6-receptor mRNA synthesis was stimulated by dexamethasone, IL-6 or IL-1 [208] . Interestingly, in normal peripheral blood monocytes the synthesis of IL-6-receptor mRNA is strongly reduced by IL-6, IL-I and lipopolysaccharide [208] was claimed to involve protein kinase C [209] , it has been shown by pretreatment of HepG2 cells with phorbol ester that the action of IL-6 was independent of protein kinase C activity [204] . Preliminary experiments from our laboratory gave no evidence for the involvement of protein kinase C, inositol trisphosphate and adenylate cylase in the IL-6-mediated signal transduction.
INTERLEUKIN-6-RESPONSIVE ELEMENTS IN ACUTE PHASE PROTEIN GENES
To further understand the mechanisms of acute phase protein induction by IL-6, the promoter regions of acute phase proteins have been isolated and ligated to suitable reporter genes. By transfection experiments with deletion mutants it was possible to define cis-elements responsible for the induction of acute phase protein gene transcription by IL-6. In the case of the rat al-acid glycoprotein gene an IL-6-responsive enhancer element with a 142 bp sequence located 5300-5150 bp upstream of the transcriptional start site was identified [210] . Two IL-6-responsive elements, between -852 and -777 and between -336 and -165 upstream from the cap site were identified in the rat a2-macroglobulin gene [211] (Fig. 6 ). In the human haptoglobin gene three responsive elements around -157, -111 and -61 have been described [212] . The IL-6-responsive elements of a,-acid glycoprotein-, a2-macroglobulin and haptoglobin genes contain a common sequence motif (Fig. 7) . This consensus sequence is also present in the promoter regions of rat a-, /8-and y-fibrinogen [214] , rat T-kininogen [215] , human C-reactive protein [216] , rat transthyretin [217] , murine serum amyloid A [218] and human a,-antitrypsin [219] (Fig. 7) (Fig. 8a) ligated to an SV40 promoter in front of the chloramphenicol acetyltransferase gene. Fig. 8(b) shows that the tandem of two such consensus sequences represents a particularly strong IL-6 responsive element.
As a consequence of the IL-6-induced increase in transcription [210] [211] [212] [213] 220] , elevated mRNA [40, 46, [48] [49] [50] [51] 53, 204, 217] , and acute phase protein [38, 41, [47] [48] [49] [50] [52] [53] [54] [55] 57, 59, 61, 64, 204] concentrations result. Furthermore, IL-6 was found to enhance the secretion of rat a2-macroglobulin in rat hepatocyte primary cultures [38] .
RECENT DEVELOPMENTS
Baumann et al. [19, 28] described a hepatocyte-stimulating factor, designated as HSF-III, in conditioned media from squamous carcinoma cells (COLO 16). This factor acts in an additive manner on the same spectrum of acute phase proteins as IL-6 [221] . It is structurally (molecular mass 39 kDa) and immunologically different from IL-6 and acts on a different receptor. Recently, it was shown that HSF-III is identical with leukaemia inhibitory factor (LIF) [222] .
CONCLUSION
Due to its pleiotropic action, IL-6 has been intensively studied in many laboratories. It turned out to be an important factor in the immune and in the haematopoietic system and the major mediator in the hepatic acute phase response.
In Fig. 9 we show a simplified scheme of the complex role of IL-6 within the cytokine network that controls acute phase protein synthesis in hepatocytes. Monocytes/macrophages stimulated by bacteria, lipopolysaccharide, viruses, IL-1 and yet unknown factors synthesize and secrete, among other monokines, IL-1, and TNFa (Fig. 9) . These three monokines act via specific hepatic receptors. IL-6, however, turned out to be the most potent inducer of acute phase protein synthesis in human hepatocytes. The monokines IL-I and TNFa. also stimulate fibroblasts, endothelial cells and keratinocytes to synthesize IL-6 and thus amplify its biological effects.
IL Furthermore, it is of great interest to understand the interaction of IL-6 with its hepatic receptor, the regulation of the synthesis of the IL-6-receptor and the pathways of the intracellular signal transduction.
The intracellular mechanism of acute phase protein gene activation after IL-6 stimulation of hepatocytes, in particular a functional analysis of IL-6-responsive element(s), and the isolation and characterization of transcription factors, need to be worked out in greater detail. The fascinating problem of why some proteins behave as strong acute phase reactants in animals and not in man, or vice versa, should be solved. A better knowledge of the pathophysiological mechanisms of the acute phase response will improve the treatment of inflammatory diseases in man.
